Like many pharma stocks, Eli Lilly (NYSE: LLY) offers investors a bit of safety -- and it's an element you can count on during any economic environment. This is because patients need their ...

That negative investor reaction was directed at companies involved in the white-hot weight loss drug segment of the market (Eli Lilly is the pharmaceutical giant behind a popular one, Zepbound).

Embrace the spirit of Holi 2025 with heartfelt wishes, uplifting quotes, and vibrant images for your facebook and instagram ...

Eli Lilly and Co. Wednesday announced plans to build four pharmaceutical manufacturing sites in the United States, significantly boosting domestic medicine production and adding around 13,000 ...

Feb. 26 (UPI) --Eli Lilly announced plans for four new pharmaceutical manufacturing sites to produce domestic medicine production in the United States and make the nation the world's leader in ...

A new high-profile event dedicated to global TV series is being launched in Italy with “Bridgerton” star Adjoa Andoh, Evangeline Lilly (“Lost”) and Italy’s ‘Godfather of Disco ...

Some social media users said that they almost had to turn the program off they were so uncomfortable with the Lilly Singh's interview with Jane Fonda. Jane, 87, attended the award ceremony to ...

Violet Affleck - the eldest daughter of Ben Affleck and Jennifer Garner - has reportedly cut ties with her ex-stepmum over worries she was used as a “pawn.” Ben, 52, married Jennifer Lopez, 55 ...

Regarding weight loss, Lilly in June 2023 unveiled phase 2 data showing orforglipron helped patients with obesity lose up to 14.7% of their body weight at 36 weeks compared to placebo. While those ...

Eli Lilly & Co. said Tuesday it’s cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity for patients who have to pay for the drug themselves. It said it will ...

Eli Lilly plans to invest at least $27 billion to build four new pharmaceutical manufacturing sites in the U.S. The drugmaker, which had committed to $23 billion in domestic investments from 2020 ...

Eli Lilly has acquired Organovo’s lead asset, a clinical FXR agonist designed to treat inflammatory bowel disease (IBD), in a deal worth up to $50 million in biobucks. Organovo’s stock ...